Engineering AAV Lead Vectors for Gene Therapy
Sponsored by: SIRION BIOTECH
- Vector Design
- rAAV factors
Date: 16 March
Time: 2PM London / 3PM CET
Optimizing vector design at R&D and preclinical stages for improved safety and efficacy
The rAAV vector design affects not only the duration and localization of the therapeutic sequence transcription, but also manufacturing scalability and generation of manufacturing by-products, such as process- and product-related impurities, that compromise the safety and efficacy of rAAV vector particles.
SIRION BIOTECH will illustrate via gap analysis case studies how undersized rAAV vectors affect the level of process-related impurities such as co-packaged DNA plasmid sequences. Experimental data will be also presented to compare design strategies, such as adding “DNA stuffer sequences”, to minimize this safety concern. We will also discuss case studies in which oversized rAAV vectors are the root cause of suboptimal rAAV batch potency due to high levels of product-related impurities. Strategies for analytical quantification of these type of impurities will also be demonstrated with experimental data.
In addition to the impact on quality and safety, rAAV vector design contributes to the therapeutic sequence expression level and persistence in the target tissue. We will exemplify this point by focusing on the promoter element.
Join SIRION BIOTECH´s Dr Michael Salomon and Dr Irene Ferreira as they discuss the strategies for engineering rAAV lead vectors for gene therapy that address safety and efficacy requirements.
Dr Michael Salomon,
Senior Vice President, Development
Michael joined SIRION Biotech in 2007. He is heading the SIRION´s unit with Viral vector engineering, Process Development, Manufacturing and QC departments. Michael received his PhD from LMU in Munich, Germany.
Dr Irene Ferreira,
Head of Clinical Support, Cell and Gene Therapy
Irene Joined SIRION BIOTECH in 2017. She is heading SIRION´s department responsible for Cell and Gene Therapy projects, including the development of AAV lead vectors. Irene received her PhD from the Max Planck Institute of Biochemistry and LMU in Munich, Germany.
Key Learning Objectives
- The safety challenges of undersized and oversized rAAV vectors and design strategies to address them.
- The impact of rAAV vector design on manufacturing productivity and batch potency.
- The contribution of rAAV vector design to the therapeutic sequence expression level and persistence in the target tissue.
- Head of Research and Development Viral Vectors
- Head of Research and Development Gene therapy
- Head of Research and Development Viral technology
- Group Head Viral vectors
- Group Head viral technology
- Head of Discovery
- Head of Development
- Vector Biology and Discovery Lead